Tag: digest

ISAD Beijing 2026 Annual Meeting Final Preparations for the 16th Georg Rajka ISAD Symposium All registered participants will receive their personal electronic ticket via email between October 5 and 8, enabling them to fine tune their registration. Please remember to check your spam folder and contact us on October 9 if you have not received […]

Periostin in atopic dermatitis: the “Purloined Letter” hiding in plain sight? Twenty years after linking periostin to IL-4/IL-13–driven airway remodeling in asthma [1], Izuhara and colleagues revisit a story they helped initiate [2]. The situation recalls Edgar Allan Poe’s The Purloined Letter, in which the object everyone is searching for escapes detection precisely because it […]

Standardizing the approach without standardizing the patient The rapid expansion of effective systemic treatments has made Treat-to-Target a natural next step in atopic dermatitis. Once substantial improvement becomes achievable for many patients, it is no longer sufficient to ask whether a treatment works. We must determine what level of control should be reached, when it […]

S. aureus and Eczema Herpeticum: A Laboratory Paradox, a Bedside Emergency Eczema herpeticum, or Kaposi-Juliusberg syndrome caused by HSV-1, is one of the situations in atopic dermatitis where clinical hesitation can be dangerous. Dermatologists who have seen severe cases remember the picture well: sudden painful monomorphic vesicles or punched-out erosions on eczematous skin, fever, facial […]

From “Response” to “Reassurance” Topical corticosteroids (TCS) remain the cornerstone of atopic dermatitis (AD) management worldwide. Yet, despite decades of clinical use, a paradox persists: while clinicians rely on TCS as first-line therapy, many patients remain uncertain, and sometimes fearful, about how to use them safely over time. This tension is increasingly visible in discussions […]

Pediatric Atopic Dermatitis Guidelines in 2026:Convergence of Evidence, Divergence of Practice The recent JAAD 2026 guidelines on pediatric atopic dermatitis DOI: 10.1016/j.jaad.2026.02.114, led by the late Robert Sidbury, marks an important milestone: it is the first fully evidence-graded, pediatric-specific update in the era of biologics and JAK inhibitors. Built on a strict GRADE methodology and largely restricted […]

Beyond the “All-TH2” Paradigm in Atopic Dermatitis For more than two decades, atopic dermatitis (AD) has largely been interpreted through the framework of type-2 immunity. IL-4, IL-13, IgE, and eosinophils became the canonical pathway explaining disease pathogenesis and guiding therapeutic development. The remarkable clinical success of IL-4/IL-13 blockade has reinforced this paradigm. Yet both the […]

The Ethics of Prescribing and Access in Atopic Dermatitis: Can We Separate Them? Therapeutic innovation in atopic dermatitis (AD) has advanced rapidly. Biologics and targeted therapies have transformed the outlook for patients with severe disease. Yet a central ethical tension is emerging: what is the value of prescribing the best treatment if patients cannot access […]